REGNÂ – Regeneron Pharmaceuticals, Inc.
Float Short %
2.77
Margin Of Safety %
25
Put/Call OI Ratio
0.68
EPS Next Q Diff
-3.81
EPS Last/This Y
-1.53
EPS This/Next Y
-3.4
Price
559.97
Target Price
727.87
Analyst Recom
1.61
Performance Q
7.31
Relative Volume
0.61
Beta
0.31
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | REGN | 580.39 | 0.74 | 0.73 | 46391 |
| 2025-08-18 | REGN | 574.05 | 0.78 | 0.83 | 40242 |
| 2025-08-19 | REGN | 571.45 | 0.78 | 1.16 | 42228 |
| 2025-08-20 | REGN | 591.34 | 0.80 | 1.12 | 42723 |
| 2025-08-21 | REGN | 598.25 | 0.77 | 0.78 | 43844 |
| 2025-08-22 | REGN | 589.55 | 0.77 | 0.88 | 44218 |
| 2025-08-25 | REGN | 573.38 | 0.70 | 0.47 | 40490 |
| 2025-08-26 | REGN | 587.57 | 0.70 | 0.78 | 41487 |
| 2025-08-27 | REGN | 586.46 | 0.70 | 0.14 | 42138 |
| 2025-08-28 | REGN | 579.85 | 0.69 | 0.34 | 42760 |
| 2025-08-29 | REGN | 580.9 | 0.69 | 1.01 | 43194 |
| 2025-09-02 | REGN | 577.79 | 0.68 | 1.12 | 41663 |
| 2025-09-03 | REGN | 563.66 | 0.69 | 0.83 | 42728 |
| 2025-09-04 | REGN | 567.16 | 0.69 | 1.10 | 43497 |
| 2025-09-05 | REGN | 572.38 | 0.68 | 0.93 | 43673 |
| 2025-09-08 | REGN | 558.24 | 0.68 | 0.70 | 42702 |
| 2025-09-09 | REGN | 556.73 | 0.68 | 1.01 | 43429 |
| 2025-09-10 | REGN | 555.77 | 0.69 | 0.31 | 44099 |
| 2025-09-11 | REGN | 567.79 | 0.68 | 0.47 | 44331 |
| 2025-09-12 | REGN | 559 | 0.68 | 0.67 | 44585 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | REGN | 580.37 | -22.5 | -1025.9 | 39.43 |
| 2025-08-18 | REGN | 573.93 | -22.4 | -1176.2 | 39.43 |
| 2025-08-19 | REGN | 571.78 | -22.4 | -1145.6 | 39.42 |
| 2025-08-20 | REGN | 591.16 | -22.4 | -991.3 | 39.42 |
| 2025-08-21 | REGN | 598.30 | -22.4 | -1079.9 | 39.42 |
| 2025-08-22 | REGN | 589.35 | -22.4 | -1190.6 | 39.42 |
| 2025-08-25 | REGN | 572.49 | -22.4 | -1248.4 | 39.42 |
| 2025-08-26 | REGN | 587.65 | -22.4 | -1020.9 | 39.42 |
| 2025-08-27 | REGN | 586.92 | -22.4 | -1135.5 | 39.42 |
| 2025-08-28 | REGN | 579.61 | -22.4 | -1181.7 | 39.42 |
| 2025-08-29 | REGN | 580.90 | -22.4 | -1121.3 | 39.42 |
| 2025-09-02 | REGN | 577.76 | -22.4 | -1151.2 | 39.42 |
| 2025-09-03 | REGN | 563.54 | -22.4 | 60.8 | 39.42 |
| 2025-09-04 | REGN | 567.05 | -22.4 | 230.5 | 39.42 |
| 2025-09-05 | REGN | 573.38 | -22.6 | 267.3 | 39.37 |
| 2025-09-08 | REGN | 558.44 | -22.6 | 54.1 | 39.37 |
| 2025-09-09 | REGN | 556.60 | -22.6 | 180.2 | 39.37 |
| 2025-09-10 | REGN | 555.79 | -22.6 | 191.1 | 39.37 |
| 2025-09-11 | REGN | 568.20 | -22.6 | 322.3 | 39.37 |
| 2025-09-12 | REGN | 559.97 | -22.6 | 118.0 | 39.37 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | REGN | 0.00 | -0.47 | 2.24 |
| 2025-08-18 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-19 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-20 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-21 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-22 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-25 | REGN | 0.00 | -3.71 | 2.24 |
| 2025-08-26 | REGN | 0.00 | -3.71 | 2.24 |
| 2025-08-27 | REGN | 0.00 | -3.71 | 2.30 |
| 2025-08-28 | REGN | 0.00 | -3.71 | 2.30 |
| 2025-08-29 | REGN | 0.00 | -3.71 | 2.30 |
| 2025-09-02 | REGN | 0.00 | -3.68 | 2.30 |
| 2025-09-03 | REGN | 0.00 | -3.68 | 2.30 |
| 2025-09-04 | REGN | 0.00 | -3.68 | 2.30 |
| 2025-09-05 | REGN | 0.00 | -3.68 | 2.30 |
| 2025-09-08 | REGN | 0.00 | -4.39 | 2.30 |
| 2025-09-09 | REGN | 0.00 | -4.39 | 2.30 |
| 2025-09-10 | REGN | 0.00 | -4.39 | 2.30 |
| 2025-09-11 | REGN | 0.00 | -4.39 | 2.77 |
| 2025-09-12 | REGN | 0.00 | -4.39 | 2.77 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
12.89
Avg. EPS Est. Current Quarter
9.64
Avg. EPS Est. Next Quarter
9.08
Insider Transactions
Institutional Transactions
-4.39
Beta
0.31
Average Sales Estimate Current Quarter
3566
Average Sales Estimate Next Quarter
3605
Fair Value
699.2
Quality Score
99
Growth Score
82
Sentiment Score
27
Actual DrawDown %
53.8
Max Drawdown 5-Year %
-59.7
Target Price
727.87
P/E
14.11
Forward P/E
13.91
PEG
10.77
P/S
4.18
P/B
1.99
P/Free Cash Flow
15.4
EPS
39.69
Average EPS Est. Cur. Y​
39.37
EPS Next Y. (Est.)
35.98
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
31.37
Relative Volume
0.61
Return on Equity vs Sector %
-10
Return on Equity vs Industry %
3.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.1
EBIT Estimation
118
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15182
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading